{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:06:40Z","timestamp":1784804800868,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1124\/dmd.113.052316","type":"journal-article","created":{"date-parts":[[2013,5,15]],"date-time":"2013-05-15T03:51:48Z","timestamp":1368589908000},"page":"1488-1493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Comparison of Endogenous 4\u03b2-Hydroxycholesterol with Midazolam as Markers for CYP3A4 Induction by Rifampicin"],"prefix":"10.1016","volume":"41","author":[{"given":"Linda","family":"Bj\u00f6rkhem-Bergman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"B\u00e4ckstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Nyl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"R\u00f6nquist-Nii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Bredberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy B.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Bertilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Diczfalusy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.113.052316_bib1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1528-1157.1996.tb00021.x","article-title":"Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin","volume":"37","author":"Backman","year":"1996","journal-title":"Epilepsia"},{"key":"10.1124\/dmd.113.052316_bib2","doi-asserted-by":"crossref","first-page":"38685","DOI":"10.1074\/jbc.M105127200","article-title":"Antiepileptic drugs increase plasma levels of 4\u03b2-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4","volume":"276","author":"Bodin","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.113.052316_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2125.2008.03309.x","article-title":"4\u03b2-hydroxycholesterol as an endogenous marker for CYP3A4\/5 activity. Stability and half-life of elimination after induction with rifampicin","volume":"67","author":"Diczfalusy","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.052316_bib4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/FPC.0b013e3282f50ee9","article-title":"4\u03b2-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians","volume":"18","author":"Diczfalusy","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.113.052316_bib5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2125.2010.03773.x","article-title":"4\u03b2-Hydroxycholesterol, an endogenous marker of CYP3A4\/5 activity in humans","volume":"71","author":"Diczfalusy","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.052316_bib6","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.jchromb.2010.04.001","article-title":"Development and validation of a rapid and sensitive assay for simultaneous quantification of midazolam, 1\u2032-hydroxymidazolam, and 4-hydroxymidazolam by liquid chromatography coupled to tandem mass-spectrometry","volume":"878","author":"Dostalek","year":"2010","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/dmd.113.052316_bib7","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s00228-007-0365-6","article-title":"Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation","volume":"63","author":"Fromm","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.113.052316_bib8","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.clpt.6100050","article-title":"Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the \u201ccocktail\u201d approach","volume":"81","author":"Fuhr","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.052316_bib9","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00228-003-0690-3","article-title":"Urinary 6\u03b2-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals","volume":"59","author":"Galteau","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.113.052316_bib10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.qai.0000167156.44980.33","article-title":"Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study","volume":"39","author":"Gerber","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/dmd.113.052316_bib11","article-title":"Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients","author":"Habtewold","year":"2012","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/dmd.113.052316_bib12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5414\/CP201831","article-title":"Genotype-phenotype variability in human CYP3A locus in Nepalese people residing in Bangladesh","volume":"51","author":"Hassan","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.052316_bib13","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00228-008-0492-8","article-title":"CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4\u03b2-hydroxycholesterol levels","volume":"64","author":"Josephson","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.113.052316_bib14","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.jchromb.2011.04.009","article-title":"Determination of midazolam and 1-hydroxymidazolam from plasma by gas chromatography coupled to methane negative chemical ionization mass spectrometry after sublingual administration of midazolam","volume":"879","author":"Kaartama","year":"2011","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/dmd.113.052316_bib15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/clpt.2008.132","article-title":"Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4\u03b2-hydroxycholesterol","volume":"84","author":"Kanebratt","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.052316_bib16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/sj.clpt.6100237","article-title":"Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam","volume":"82","author":"Kharasch","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.052316_bib17","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1177\/0091270009354997","article-title":"Influence of CYP3A5 and MDR1 genetic polymorphisms on urinary 6 \u03b2-hydroxycortisol\/cortisol ratio after grapefruit juice intake in healthy Chinese","volume":"50","author":"Li","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.113.052316_bib18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.5414\/CPP47709","article-title":"4\u03b2-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man","volume":"47","author":"L\u00fctjohann","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.052316_bib22","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1111\/bcp.12016","article-title":"A comparison of 4b-hydroxycholesterol\/cholesterol and 6b-hydroxycortisol\/cortisol as markers of CYP3A4 induction","volume":"75","author":"M\u00e5rde Arrh\u00e9n","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.052316_bib19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/tpj.2009.21","article-title":"Association of genotypes of the CYP3A cluster with midazolam disposition in vivo","volume":"9","author":"Miao","year":"2009","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/dmd.113.052316_bib20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00228-003-0575-5","article-title":"Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man","volume":"59","author":"Mirghani","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.113.052316_bib21","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/01.fpc.0000230411.89973.1b","article-title":"CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population","volume":"16","author":"Mirghani","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.113.052316_bib23","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11481-006-9034-2","article-title":"MDR- and CYP3A4-mediated drug-drug interactions","volume":"1","author":"Pal","year":"2006","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1124\/dmd.113.052316_bib24","first-page":"1079","article-title":"Single plasma concentrations of 1\u2032-hydroxymidazolam or the ratio of 1\u2032-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects","volume":"42","author":"Rogers","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.113.052316_bib25","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00228-008-0503-9","article-title":"No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam","volume":"64","author":"Tomalik-Scharte","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.113.052316_bib26","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1365-2125.2007.03078.x","article-title":"Time course of the increase in 4\u03b2-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy","volume":"65","author":"Wide","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.052316_bib27","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jchromb.2010.03.026","article-title":"Simultaneous determination of tolbutamide, omeprazole, midazolam and dextromethorphan in human plasma by LC-MS\/MS\u2014a high throughput approach to evaluate drug-drug interactions","volume":"878","author":"Zhang","year":"2010","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624097794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624097794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.113.052316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:10:19Z","timestamp":1739905819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624097794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0090955624097794"],"URL":"https:\/\/doi.org\/10.1124\/dmd.113.052316","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Endogenous 4\u03b2-Hydroxycholesterol with Midazolam as Markers for CYP3A4 Induction by Rifampicin","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.113.052316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2013 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}